First human test for new prostate cancer imaging agent
Diagnosis
Completed
This study is testing a new imaging agent called 68Ga-NTA-476 for PET scans in men with prostate cancer. It's the first time this agent is being used in people. The main goals are to see where the agent travels in the body after injection, how it compares to the current standard …
Phase: EARLY_PHASE1 • Sponsor: Melbourne Theranostic Innovation Centre • Aim: Diagnosis
Last updated Mar 31, 2026 12:12 UTC